First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry Age Related Macular Degeneration

NCT04246866 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Dry Age-related Macular Degeneration
Geographic Atrophy
Macular Degeneration
Retinal Disease
Retinal Degeneration

Interventions

BIOLOGICAL: GEM103

Sponsor

Gemini Therapeutics, Inc.